MX339241B - Vacunas novedosas contra sub-tipos multiples de virus de influenza. - Google Patents
Vacunas novedosas contra sub-tipos multiples de virus de influenza.Info
- Publication number
- MX339241B MX339241B MX2013003382A MX2013003382A MX339241B MX 339241 B MX339241 B MX 339241B MX 2013003382 A MX2013003382 A MX 2013003382A MX 2013003382 A MX2013003382 A MX 2013003382A MX 339241 B MX339241 B MX 339241B
- Authority
- MX
- Mexico
- Prior art keywords
- dna plasmid
- mammal
- consensus
- influenza virus
- immune response
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a vacunas de ADN de plásmido capaces de generar en un mamífero una respuesta inmune contra una pluralidad de subtipos de virus de influenza, que comprenden un ADN de plásmido y un excipiente farmacéuticamente aceptable. El ADN de plásmido es capaz de expresar un antígeno de influenza consensual en una célula del mamífero en una cantidad efectiva para producir una respuesta inmune en el mamífero, en donde el antígeno de influenza consensual comprende hemaglutinina consensual (HA), neuraminidasa (NA), proteína de matriz, nucleoproteína, ectodominio-nucleo-proteína M2 (M2e-NP), o una combinación de los mismos. Preferiblemente, el antígeno de influenza consensual comprende HA, MA, M2e-NP, o una combinación de los mismos. El ADN de plásmido comprende un promotor operablemente enlazado a una secuencia de codificación que codifica el antígeno de influenza consensual. De manera adicional, un aspecto de la presente invención incluye métodos para producir una respuesta inmune contra una pluralidad de subtipos de virus de influenza en un mamífero usando las vacunas de ADN de plásmido provistas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US98728407P | 2007-11-12 | 2007-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX339241B true MX339241B (es) | 2016-05-18 |
Family
ID=40718429
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005229A MX2010005229A (es) | 2007-11-12 | 2008-11-12 | Vacunas novedosas contra sub-tipos multiples de virus de influenza. |
MX2013003382A MX339241B (es) | 2007-11-12 | 2010-05-12 | Vacunas novedosas contra sub-tipos multiples de virus de influenza. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010005229A MX2010005229A (es) | 2007-11-12 | 2008-11-12 | Vacunas novedosas contra sub-tipos multiples de virus de influenza. |
Country Status (10)
Country | Link |
---|---|
US (4) | US9592285B2 (es) |
EP (1) | EP2217064A4 (es) |
JP (5) | JP5705545B2 (es) |
KR (1) | KR101255419B1 (es) |
CN (1) | CN101877965B (es) |
AU (1) | AU2008331673B2 (es) |
CA (1) | CA2705461A1 (es) |
HK (1) | HK1149176A1 (es) |
MX (2) | MX2010005229A (es) |
WO (1) | WO2009073330A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008331673B2 (en) * | 2007-11-12 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
CA2735724C (en) | 2008-06-19 | 2018-07-24 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
US20110097418A1 (en) * | 2009-05-29 | 2011-04-28 | Variation Biotechnologies, Inc. | Compositions and methods for treating influenza |
KR20210149203A (ko) * | 2009-11-02 | 2021-12-08 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 구제역 바이러스(fmdv) 공통 단백질, 이를 위한 코딩 서열 및 이로부터 만들어진 백신 |
US8298820B2 (en) * | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
US20110184160A1 (en) * | 2010-01-26 | 2011-07-28 | Weiner David B | Nucleic acid molecule encoding consensus influenza a hemagglutinin h1 |
CN101892248B (zh) * | 2010-04-29 | 2012-04-18 | 王世霞 | 禽流感h5 ha抗原的单克隆抗体 |
EP2616545B1 (en) * | 2010-09-14 | 2018-08-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
PT2672992T (pt) | 2011-02-11 | 2020-07-27 | Univ Pennsylvania | Molécula de ácidos nucleicos codificando proteína nuclear do vírus da hepatite b e vacina compreendendo a mesma |
CN103732749B (zh) | 2011-06-20 | 2017-03-29 | 高等教育联邦系统-匹兹堡大学 | 计算优化的宽反应性的h1n1流感抗原 |
JP6567824B2 (ja) * | 2011-10-12 | 2019-08-28 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
BR112014018884A2 (pt) | 2012-02-07 | 2017-07-04 | Univ Pittsburgh Commonwealth Sys Higher Education | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b |
CA2863949C (en) | 2012-02-13 | 2021-06-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
AU2013240365B2 (en) | 2012-03-30 | 2017-03-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for H5N1 and H1N1 influenza viruses |
EP2836505B1 (en) | 2012-04-10 | 2019-01-23 | The Trustees Of The University Of Pennsylvania | Human respiratory syncytial virus concensus antigens, nucleic acid constructs and vaccines made thereform, and methods of using same |
US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
JP2016505538A (ja) * | 2012-11-27 | 2016-02-25 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | H1n1インフルエンザに対する計算で最適化した広い反応性を示す抗原 |
JP6373573B2 (ja) * | 2012-12-05 | 2018-08-15 | 三星ディスプレイ株式會社Samsung Display Co.,Ltd. | アミン誘導体、有機発光材料及びそれを用いた有機エレクトロルミネッセンス素子 |
JP6517779B2 (ja) | 2013-03-12 | 2019-05-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスの改良型ワクチンおよびその使用方法 |
KR20150127586A (ko) | 2013-03-15 | 2015-11-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 인플루엔자 핵산 분자 및 이로부터 제조된 백신 |
BR112015022582B1 (pt) | 2013-03-15 | 2024-01-09 | The Trustees Of The University Of Pennsylvania | Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo |
CN105246491B (zh) * | 2013-03-15 | 2019-04-19 | 宾夕法尼亚大学理事会 | 针对多种登革病毒亚型的新颖疫苗 |
AU2014228497B2 (en) * | 2013-03-15 | 2017-03-02 | Inovio Pharmaceuticals, Inc. | Novel vaccines against multiple subtypes of dengue virus |
CN103421843B (zh) * | 2013-07-29 | 2015-12-09 | 中国农业科学院哈尔滨兽医研究所 | 编码h5n1亚型禽流感同义血凝素(ha)蛋白以及同义神经氨酸酶(na)蛋白的基因及其应用 |
KR101723605B1 (ko) * | 2014-10-21 | 2017-04-07 | 진원생명과학 주식회사 | 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법 |
EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
CN106039303A (zh) * | 2016-06-20 | 2016-10-26 | 华南农业大学 | 一种h5亚型禽流感dna疫苗及其制备方法 |
JP6795468B2 (ja) * | 2017-07-14 | 2020-12-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
CN111526886A (zh) * | 2017-10-27 | 2020-08-11 | 国家血清研究所 | 多基因流感疫苗 |
EP3773709A4 (en) * | 2018-03-28 | 2021-12-29 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising neuraminidase |
WO2020014656A1 (en) * | 2018-07-13 | 2020-01-16 | University Of Georgia Research Foundation | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof |
EP3921332A2 (en) * | 2019-02-08 | 2021-12-15 | The USA, as represented by The Secretary, Department of Health and Human Services | Nanoparticle-based influenza virus vaccines and uses thereof |
WO2020198329A1 (en) | 2019-03-25 | 2020-10-01 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
KR102326037B1 (ko) | 2019-04-18 | 2021-11-12 | 충북대학교 산학협력단 | H5 인플루엔자를 치료 또는 예방하기 위한 펩타이드 및 이를 암호화하는 코돈 최적화 서열, 및 이를 이용한 백신 |
JP7075130B2 (ja) * | 2019-10-25 | 2022-05-25 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | ヒトパピローマウイルスのワクチンおよびその使用方法 |
CN113461786B (zh) * | 2020-03-30 | 2022-09-13 | 普莱柯生物工程股份有限公司 | 一种禽流感病毒样颗粒疫苗、及其制备方法和应用 |
WO2023019274A1 (en) * | 2021-08-13 | 2023-02-16 | Purdue Research Foundation | Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
ATE302854T1 (de) | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5846806A (en) * | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
EP0996717B1 (en) * | 1997-08-05 | 2005-12-07 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoprotective influenza antigen and its use in vaccination |
WO1999024640A1 (fr) | 1997-11-12 | 1999-05-20 | Hitachi, Ltd. | Procede de surveillance de corps etrangers dans un dispositif de traitement par plasma |
AU2002211490A1 (en) * | 2000-10-04 | 2002-04-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
JP2005525792A (ja) * | 2001-12-21 | 2005-09-02 | ゲンパト77 ファーマコジェネティクス エージー | 免疫関連疾患および他の疾患に用いる治療的抗tirc7抗体 |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
JP2005523698A (ja) * | 2002-04-26 | 2005-08-11 | メディミューン・ヴァクシンズ・インコーポレーテッド | インフルエンザウイルスの生産用多重プラスミドシステム |
CA2504593C (en) | 2002-11-04 | 2016-08-09 | Advisys, Inc. | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
CA2517181C (en) | 2003-02-25 | 2013-07-16 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
EP1628749B1 (en) | 2003-05-30 | 2019-07-31 | VGXI, Inc. | Devices and methods for biomaterial production |
CA2566355C (en) * | 2004-05-18 | 2014-04-15 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
GB0507997D0 (en) | 2005-02-01 | 2005-05-25 | Powderject Vaccines Inc | Nucleic acid constructs |
EP1851238A4 (en) * | 2005-02-24 | 2008-12-31 | Univ Massachusetts | FLUID NUCLEIC ACIDS, POLYPEPTIDES AND USES THEREOF |
EP2374892B1 (en) * | 2005-04-29 | 2018-02-14 | University of Cape Town | Expression of viral proteins in plants |
EP1909829A4 (en) * | 2005-07-19 | 2009-11-11 | Dow Global Technologies Inc | RECOMBINANT GRIP VACCINES |
US20070116717A1 (en) * | 2005-08-01 | 2007-05-24 | Shneider Alexander M | Influenza vaccine compositions and methods |
PT1937301E (pt) * | 2005-10-18 | 2015-09-14 | Novavax Inc | Partículas idênticas a vírus (vlps) da gripe funcionais |
WO2007100584A2 (en) | 2006-02-16 | 2007-09-07 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antiviral agents and vaccines against influenza |
CN1810961B (zh) * | 2006-02-22 | 2010-05-12 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种重组流感病毒及其制备方法与应用 |
CA2541872A1 (en) * | 2006-04-26 | 2007-10-26 | Institut Pasteur | H5 pseudotyped viruses and uses thereof |
CA2659262C (en) * | 2006-07-28 | 2017-01-10 | The Trustees Of The University Of Pennsylvania | Improved hpv vaccines and methods for using the same |
WO2008048632A1 (en) | 2006-10-17 | 2008-04-24 | Vgx Pharmaceuticals, Inc. | Electroporation devices and methods of using same for electroporation of cells in mammals |
WO2008091657A1 (en) * | 2007-01-23 | 2008-07-31 | Academia Sinica | Flu vaccines and methods of use thereof |
WO2008124331A1 (en) * | 2007-04-03 | 2008-10-16 | Cytogenix, Inc. | Novel sequences and dna vaccines against avian flu |
AU2008331673B2 (en) * | 2007-11-12 | 2014-12-11 | The Trustees Of The University Of Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
WO2013177533A1 (en) * | 2012-05-25 | 2013-11-28 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
-
2008
- 2008-11-12 AU AU2008331673A patent/AU2008331673B2/en not_active Ceased
- 2008-11-12 EP EP08857297A patent/EP2217064A4/en not_active Withdrawn
- 2008-11-12 US US12/269,824 patent/US9592285B2/en active Active
- 2008-11-12 KR KR1020107012899A patent/KR101255419B1/ko active IP Right Grant
- 2008-11-12 CA CA2705461A patent/CA2705461A1/en not_active Abandoned
- 2008-11-12 MX MX2010005229A patent/MX2010005229A/es active IP Right Grant
- 2008-11-12 CN CN200880118583.0A patent/CN101877965B/zh not_active Expired - Fee Related
- 2008-11-12 JP JP2010533340A patent/JP5705545B2/ja not_active Expired - Fee Related
- 2008-11-12 WO PCT/US2008/083281 patent/WO2009073330A2/en active Application Filing
-
2010
- 2010-05-12 MX MX2013003382A patent/MX339241B/es unknown
-
2011
- 2011-04-07 HK HK11103561.0A patent/HK1149176A1/xx not_active IP Right Cessation
- 2011-06-10 US US13/158,150 patent/US8133723B2/en active Active
-
2013
- 2013-09-04 JP JP2013182786A patent/JP2013247962A/ja active Pending
-
2015
- 2015-03-27 JP JP2015065957A patent/JP6047610B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-05 JP JP2016000345A patent/JP6195943B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-26 US US15/416,604 patent/US10076565B2/en active Active
- 2017-08-16 JP JP2017157133A patent/JP6549194B2/ja not_active Expired - Fee Related
-
2018
- 2018-08-01 US US16/051,725 patent/US20180333480A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016052333A (ja) | 2016-04-14 |
JP2013247962A (ja) | 2013-12-12 |
US9592285B2 (en) | 2017-03-14 |
US20170165353A1 (en) | 2017-06-15 |
KR101255419B1 (ko) | 2013-04-17 |
HK1149176A1 (en) | 2011-09-30 |
WO2009073330A2 (en) | 2009-06-11 |
AU2008331673A1 (en) | 2009-06-11 |
EP2217064A4 (en) | 2012-10-03 |
US20180333480A1 (en) | 2018-11-22 |
JP6047610B2 (ja) | 2016-12-21 |
CA2705461A1 (en) | 2009-06-11 |
JP2015120753A (ja) | 2015-07-02 |
MX2010005229A (es) | 2010-11-05 |
JP5705545B2 (ja) | 2015-04-22 |
JP6195943B2 (ja) | 2017-09-13 |
CN101877965B (zh) | 2014-08-20 |
EP2217064A2 (en) | 2010-08-18 |
JP6549194B2 (ja) | 2019-07-24 |
US10076565B2 (en) | 2018-09-18 |
US20090169505A1 (en) | 2009-07-02 |
CN101877965A (zh) | 2010-11-03 |
AU2008331673B2 (en) | 2014-12-11 |
JP2017210482A (ja) | 2017-11-30 |
JP2011506272A (ja) | 2011-03-03 |
KR20100096164A (ko) | 2010-09-01 |
US20110305664A1 (en) | 2011-12-15 |
WO2009073330A3 (en) | 2010-01-07 |
US8133723B2 (en) | 2012-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX339241B (es) | Vacunas novedosas contra sub-tipos multiples de virus de influenza. | |
Haynes | Influenza virus-like particle vaccines | |
Magini et al. | Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge | |
US20200330584A1 (en) | Computationally optimized broadly reactive antigens for influenza | |
Kang et al. | Influenza vaccines based on virus-like particles | |
Zheng et al. | Development of universal influenza vaccines based on influenza virus M and NP genes | |
MX2010007461A (es) | Nuevas vacunas contra multiples subtipos del virus del dengue. | |
JP2020039347A (ja) | 新規多価ナノ粒子に基づくワクチン | |
Subbarao et al. | The prospects and challenges of universal vaccines for influenza | |
Wiersma et al. | Developing universal influenza vaccines: hitting the nail, not just on the head | |
Stachyra et al. | DNA vaccines against influenza | |
BR112013032723A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para influenza h1n1 | |
MX346862B (es) | Secuencias consenso de envoltura de vih y método para usar las mismas. | |
AR077757A1 (es) | Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion | |
MY180109A (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
Elbahesh et al. | Broadly protective influenza vaccines: design and production platforms | |
MX345150B (es) | Antigenos ampliamente reactivos computacionalmente optimizados para virus de influenza h5n1 y h1n1. | |
IN2014DN05805A (es) | ||
Singh et al. | Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target | |
Isakova-Sivak et al. | Influenza vaccine: Progress in a vaccine that elicits a broad immune response | |
WO2012082803A3 (en) | Method for inducing an immune response against avian, swine, spanish, h1n1, h5n9 influenza viruses and formulations thereof | |
Fox et al. | Extending the breadth of influenza vaccines: status and prospects for a universal vaccine | |
Ju et al. | Heat shock protein gp96 adjuvant induces T cell responses and cross-protection to a split influenza vaccine | |
JP2010506926A5 (es) | ||
Vemula et al. | Beta-defensin 2 enhances immunogenicity and protection of an adenovirus-based H5N1 influenza vaccine at an early time |